BioStem Establishes National Pricing for Vendaje AC® Across All MAC Regions
The MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, BioStem Technologies, Inc. (BSEM) has announced that the Center for Medicare Services (CMS) has established national pricing for its allograft product, Vendaje AC® in all Medicare Administrative Contractor (MAC) regions.
This pricing announcement effective as of October 1, 2024, allows BioStem to market the Vendaje AC nationwide across all MAC regions. The product will be commercialized through a premier commercialization provider in the U.S. wound care market, Venture Medical LLC who is BioStem’s executive sales and marketing partner for AmnioWrap2®.
Jason Matuszewski, CEO of BioStem Technologies Inc., commented, “With CMS’s national pricing approval, Vendaje AC is now accessible to more patients across the country, representing a major milestone in our mission to improve advanced wound care. We are thrilled to partner with Venture Medical to bring Vendaje AC to a broader audience. Their expertise in the wound care market will be invaluable as we continue to deliver innovative solutions for patients in need.”
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap 2 ™, VENDAJE ® , VENDAJE AC ® , and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn .
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…